How I Treat
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases

HOW I APPROACH HEMATOLOGIC ABNORMALITIES IN HOSPITALIZED PATIENTS WITH INFECTIOUS DISEASES

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: October 31, 2026
0
Views
0
Downloads

Authors

Patients hospitalized with infectious diseases often develop cytopenias, coagulopathy, hyperinflammation, or tissue abnormalities that may reflect infection, treatment toxicity, organ failure, immune dysregulation, or occult hematologic disease. Drawing on 20 years of daily consultation at the National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, I organize my approach around six recurring scenarios: fever with thrombocytopenia or schistocytes; persistent cytopenia during anti-infective therapy; fever, cytopenias, and hyperferritinemia; pancytopenia prompting marrow assessment; severe anemia or hemolysis; and persistent lymphadenopathy, effusion, or unexplained inflammation, particularly in an immunocompromised patient. Across scenarios, I first identify diagnoses in which delay changes outcome, then integrate tempo, the peripheral blood smear, reticulocyte response, medication, heparin, and transfusion exposure, organ dysfunction, and immune status. Guidelines define diagnostic and therapeutic standards; experience determines how those standards are ordered, combined, and revisited when evidence is incomplete. The approach prioritizes immediate treatment of suspected thrombotic thrombocytopenic purpura, clinically significant disseminated intravascular coagulation, heparin-induced thrombocytopenia or severe drug-induced immune thrombocytopenia, acute promyelocytic leukemia, severe hemolysis, and rapidly progressive secondary hemophagocytic lymphohistiocytosis; disciplined attribution of drug toxicity; physiology-based transfusion and anticoagulation; and timely marrow or tissue diagnosis when infection no longer explains the trajectory. The goal is a reproducible, stewardship-aware bedside method.

Downloads

Download data is not yet available.

Citations

References
1. Brar RS, Schrier SL. Consultative hematology. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA, eds. Williams Hematology. 9th ed. New York, NY: McGraw-Hill Education; 2015.
2. Connell NT, Carpenter SL. Consultative hematology I: hospital-based and selected outpatient topics. In: American Society of Hematology Self-Assessment Program. 7th ed. Washington, DC: American Society of Hematology; 2019:26-60.
3. Goldman L, Lee T, Rudd P. Ten commandments for effective consultations. Arch Intern Med. 1983;143(9):1753-1755. doi:10.1001/archinte.1983.00350090131021.
4. Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, et al. The ASH Choosing Wisely campaign: five hematologic tests and treatments to question. Blood. 2013;122(24):3879-3883. doi:10.1182/blood-2013-07-518423.
5. Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005;353(5):498-507. doi:10.1056/NEJMra043442.
6. Kjeldsberg CR, ed. Practical Diagnosis of Hematologic Disorders. 5th ed. Chicago, IL: ASCP Press; 2010.
7. Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966.
8. Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812.
9. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation of the ISTH. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327-1330. doi:10.1055/s-0037-1616068.
10. Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Anesthesiology. 2020;132(5):1238-1245. doi:10.1097/ALN.0000000000003122.
11. Iba T, Levy JH, Maier CL, Helms J, Umemura Y, Moore HB, et al. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025;23(7):2356-2362. doi:10.1016/j.jtha.2025.03.038.
12. Levi M, Toh CH, Thachil J, Watson HG; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33. doi:10.1111/j.1365-2141.2009.07600.x.
13. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y.
14. Prescott HC, Antonelli M, Alhazzani W, Møller MH, Alshamsi F, Azevedo LCP, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Crit Care Med. 2026;54(4):725-812. doi:10.1097/CCM.0000000000007075.
15. Green L, Bolton-Maggs P, Beattie C, Cardigan R, Kallis Y, Stanworth SJ, et al. British Society of Haematology guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. Br J Haematol. 2018;181(1):54-67. doi:10.1111/bjh.15167.
16. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-666. doi:10.1056/NEJMra1312353.
17. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846. doi:10.1182/blood-2016-10-709857.
18. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496-2502. doi:10.1111/jth.15010.
19. Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025;23(11):3711-3732. doi:10.1016/j.jtha.2025.06.002.
20. Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. doi:10.1056/NEJMoa1806311.
21. Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489.
22. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost. 2015;41(1):49-60. doi:10.1055/s-0034-1398381.
23. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580-587. doi:10.1056/NEJMra066469.
24. Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev. 2013;27(3):137-145. doi:10.1016/j.tmrv.2013.05.005.
25. Pati I, Masiello F, Piccinini V, De Fulvio L, Massari MS, De Angelis V, et al. Risk of venous thromboembolism in infectious diseases: a literature review. Pathogens. 2025;14(8):816. doi:10.3390/pathogens14080816.
26. Bibas M, Biava G, Antinori A. HIV-associated venous thromboembolism. Mediterr J Hematol Infect Dis. 2011;3(1):e2011030. doi:10.4084/MJHID.2011.030.
27. Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225. doi:10.1182/bloodadvances.2018022954.
28. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism in patients with cancer. Blood Adv. 2021;5(4):927-974. doi:10.1182/bloodadvances.2020003442.
29. Siegal DM, Tseng EK, Schünemann HJ, Angchaisuksiri P, Cuker A, Dane K, et al. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Adv. 2025;9(6):1247-1260. doi:10.1182/bloodadvances.2024014219.
30. Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology living guidelines on anticoagulation for thromboprophylaxis in COVID-19. Blood Adv. 2021;5(3):872-888. doi:10.1182/bloodadvances.2020003763.
31. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040. doi:10.1182/blood.2020006000.
32. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters associated with poor prognosis in COVID-19. J Thromb Haemost. 2020;18(4):844-847. doi:10.1111/jth.14768.
33. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213.
34. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19(4):508-512.
35. Rodriguez-Pinto I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al. Catastrophic antiphospholipid syndrome: clinical presentation and treatment in the CAPS Registry. Autoimmun Rev. 2016;15(12):1120-1124. doi:10.1016/j.autrev.2016.09.010.
36. Centers for Disease Control and Prevention. Clinical Care of Dengue. Updated April 15, 2026. Accessed August 22, 2026. Available at: https://www.cdc.gov/dengue/hcp/clinical-care/index.html
37. Kuter DJ. Managing thrombocytopenia associated with dengue and other infections. Hematology Am Soc Hematol Educ Program. 2015;2015(1):424-429. doi:10.1182/asheducation-2015.1.424.
38. World Health Organization. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. New ed. Geneva: World Health Organization; 2009. Accessed August 22, 2026. Available at: https://www.who.int/publications/i/item/9789241547871
39. Ganz T. Anemia of inflammation. N Engl J Med. 2019;381(12):1148-1157. doi:10.1056/NEJMra1804281.
40. Cimino C, Allos BM, Phillips EJ. A review of beta-lactam-associated neutropenia and implications for cross-reactivity. Ann Pharmacother. 2021;55(8):1037-1049. doi:10.1177/1060028020975646.
41. Lam PW, Leis JA, Daneman N. Antibiotic-induced neutropenia in patients receiving outpatient parenteral antibiotic therapy. Antimicrob Agents Chemother. 2023;67(3):e0159622. doi:10.1128/aac.01596-22.
42. Laarhuis SRE, Kerskes CHM, Nijziel MR, van Wensen RJA, Touw DJ. Linezolid-induced thrombocytopenia in patients with renal impairment: a case series, review and dose advice. Drugs R D. 2024;24(1):109-115. doi:10.1007/s40268-024-00458-6.
43. Lin B, Hu Y, Xu P, Xu T, Chen C, He L, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022;10:967311. doi:10.3389/fpubh.2022.967311.
44. Abu-Zeinah G, DeSancho MT. Understanding sideroblastic anemia: an overview of genetics, epidemiology, pathophysiology and current therapeutic options. J Blood Med. 2020;11:305-318. doi:10.2147/JBM.S232644.
45. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620. doi:10.1002/art.38690.
46. La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477. doi:10.1182/blood.2018894618.
47. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. doi:10.1002/pbc.21039.
48. Opie J, Verburgh E, Bailly J, Mayne E, Louw V. Hematological complications of human immunodeficiency virus (HIV) infection: an update from an HIV-endemic setting. Open Forum Infect Dis. 2024;11(4):ofae162. doi:10.1093/ofid/ofae162.
49. Chetty C, Musekwa E, Chapanduka ZC. The value of bone marrow examinations performed in the investigation of HIV-infected patients with cytopenias. Int J Lab Hematol. 2023;45(4):553-561. doi:10.1111/ijlh.14079.
50. Kotton CN, Kumar D, Manuel O, Chou S, Hayden RT, Danziger-Isakov L, et al.; Transplantation Society International CMV Consensus Group. The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation. 2025;109(7):1066-1110. doi:10.1097/TP.0000000000005374.
51. Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, et al. Consensus Definitions of Cytomegalovirus Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clin Infect Dis. 2024;79(3):787-794. doi:10.1093/cid/ciae321.
52. Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13652. doi:10.1111/ctr.13652.
53. Rubin LG, Schaffner W. Clinical practice: care of the asplenic patient. N Engl J Med. 2014;371(4):349-356. doi:10.1056/NEJMcp1314291.
54. Ladhani SN, Fernandes S, Garg M, Borrow R, de Lusignan S, Bolton-Maggs PHB; BSH Guidelines Committee. Prevention and treatment of infection in patients with an absent or hypofunctional spleen: a British Society for Haematology guideline. Br J Haematol. 2024;204(5):1672-1686. doi:10.1111/bjh.19361.
55. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586-597. doi:10.1056/NEJMra030840.
56. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260(4):285-304. doi:10.1111/j.1365-2796.2006.01697.x.
57. Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic transfusion reactions. N Engl J Med. 2019;381(2):150-162. doi:10.1056/NEJMra1802338.
58. World Health Organization. WHO Guidelines for Malaria, 13 August 2025. Geneva: World Health Organization; 2025. Living guideline. Accessed August 22, 2026. doi:10.2471/B09514.
59. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014;383(9918):723-735. doi:10.1016/S0140-6736(13)60024-0.
60. Jaita S, Madsalae K, Charoensakulchai S, Hanboonkunupakarn B, Pengsakul T, Wilairatana P, et al. Post-artesunate delayed hemolysis: a review of current evidence. Trop Med Infect Dis. 2023;8(1):49. doi:10.3390/tropicalmed8010049.
61. Abanyie F, Arguin PM, Gutman J. Post-artesunate delayed hemolysis in patients with severe malaria treated with intravenous artesunate in the United States. Clin Infect Dis. 2023;76(3):e857-e863. doi:10.1093/cid/ciac719.
62. Crump JA, Morrissey AB, Nicholson WL, Massung RF, Stoddard RA, Galloway RL, et al. Etiology of severe non-malaria febrile illness in Northern Tanzania: a prospective cohort study. PLoS Negl Trop Dis. 2013;7(7):e2324. doi:10.1371/journal.pntd.0002324.
63. Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(11):1029-1041. doi:10.1056/NEJMra1615896.
64. Re A, Cattaneo C, Rossi G. HIV and lymphoma: from epidemiology to clinical management. Mediterr J Hematol Infect Dis. 2019;11(1):e2019004. doi:10.4084/MJHID.2019.004.
65. Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, et al. Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(10):840-859. doi:10.1016/j.annonc.2024.06.003.
66. Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177-186. doi:10.1016/B978-0-444-63849-6.00014-1.
67. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2.
68. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253. doi:10.1182/blood.2022015851.
69. Cesarman E, Chadburn A, Rubinstein PG. KSHV/HHV8-mediated hematologic diseases. Blood. 2022;139(7):1013-1025. doi:10.1182/blood.2020005470.
70. Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):75-88. doi:10.1016/j.hoc.2017.09.007.
71. Bibas M, Antinori A. EBV and HIV-related lymphoma. Mediterr J Hematol Infect Dis. 2009;1(2):e2009032. doi:10.4084/MJHID.2009.032.
72. Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, et al. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol. 2012;87(8):749-753. doi:10.1002/ajh.23236.
73. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323-2330. doi:10.1182/blood-2014-10-567479.
74. Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, et al. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. J Clin Oncol. 2022;40(35):4060-4070. doi:10.1200/JCO.22.00668.
75. Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO Provisional Clinical Opinion update. J Clin Oncol. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757.
76. Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019;37(8):677-687. doi:10.1200/JCO.18.00501.
77. Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630-1643. doi:10.1182/blood-2019-01-894980.
78. Bibas M, Lorenzini P, Cozzi-Lepri A, Calcagno A, di Giambenedetto S, Costantini A, et al. Polyclonal serum-free light chains elevation in HIV-infected patients. AIDS. 2012;26(16):2107-2110. doi:10.1097/QAD.0b013e328358d54b.
79. Bibas M, Pittalis S, Orchi N, De Carli G, Agrati C, Girardi E, et al. Prevalence of monoclonal gammopathy of undetermined significance (MGUS) at HIV diagnosis in individuals 18-40 years old: a possible HIV indicator condition. Blood Cancer J. 2021;11(5):91. doi:10.1038/s41408-021-00489-1.
80. Carson JL, Stanworth SJ, Guyatt G, Valentine S, Dennis J, Bakhtary S, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892-1902. doi:10.1001/jama.2023.12914.
81. Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371(15):1381-1391. doi:10.1056/NEJMoa1406617.
82. Metcalf RA, Nahirniak S, Guyatt G, Bathla A, White SK, Al-Riyami AZ, et al. Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines. JAMA. 2025;334(7):606-617. doi:10.1001/jama.2025.7529.

Supporting Agencies

The Italian Ministry of Health under the “Ricerca Corrente” program (IRCCS INMI L. Spallanzani, Rome, Italy

How to Cite



“HOW I APPROACH HEMATOLOGIC ABNORMALITIES IN HOSPITALIZED PATIENTS WITH INFECTIOUS DISEASES” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026085. doi:10.4084/MJHID.2026.085.